BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 27659429)

  • 1. Stem Cell Transplantation in Multiple Myeloma.
    Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
    Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of stem cell transplantation in multiple myeloma.
    Harousseau JL; Moreau P
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
    Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
    Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
    Lee HS; Min CK
    Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
    Holmberg LA; Becker PS; Bensinger W
    Acta Haematol; 2017; 137(3):123-131. PubMed ID: 28355602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for patients with newly diagnosed multiple myeloma in 2015.
    Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
    Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy in multiple myeloma.
    Harousseau JL
    Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in post-transplant maintenance treatment of multiple myeloma.
    Liu H; McCarthy P
    Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
    Malard F; Harousseau JL; Mohty M
    Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
    Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
    Gay F; Cavallo F; Palumbo A
    Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
    Maybury B; Cook G; Pratt G; Yong K; Ramasamy K
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1926-1937. PubMed ID: 27288955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies in multiple myeloma: to transplant or not?
    Preeshagul IR; Van Besien K; Mark TM
    Curr Hematol Malig Rep; 2014 Dec; 9(4):360-7. PubMed ID: 25145553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of multiple myeloma.
    Kyle RA
    Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All transplantation-eligible patients with myeloma should receive ASCT in first response.
    Moreau P; Attal M
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):250-4. PubMed ID: 25696863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.